Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Revefenacin Inhalation Solution in Healthy Chinese Volunteers
NCT05207111Phase 1Completed
- Sponsor
- Mylan
- Start
- Sep 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of revefenacin in chronic obstructive pulmonary disease (COPD), sponsored by Mylan. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity and 2 more. Started Sep 2021; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05207111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207111.